首页 > 最新文献

Frontiers in hematology最新文献

英文 中文
Economic burden of sickle cell disease in Sweden: a population-based national register study with 13 years follow up 瑞典镰状细胞病的经济负担:一项基于人群的国家登记研究,随访13年
Pub Date : 2023-06-29 DOI: 10.3389/frhem.2023.1205941
Christian Kjellander, E. Hernlund, M. Ivergård, A. Svedbom, T. Dibbern, A. Stenling, F. Sjöö, S. Vertuani, A. Glenthøj, H. Cherif
Introduction Sickle cell disease (SCD) describes a group of inherited disorders of hemoglobin. Globally, SCD occurs in approximately 300,000-400,000 births annually and is most prevalent in malaria-endemic countries. However, migration has impacted the epidemiology of SCD but data on the matter are scarce. The objective of this study was to describe the epidemiology, treatment uptake, and economic burden of SCD in Sweden, a country with substantial immigration over the last decades. Methods This nationwide retrospective observational registry cohort study identified patients with SCD from 2001 to 2018 and followed them from 2006 to 2018. Using data from high-quality population-based Swedish registers, we estimated prevalence, treatment uptake, and SCD-related health care resource use, sick leave and disability pension. Results Between 2006 and 2018 the number of patients with SCD increased from 504 to 670; inpatient hospital stays and outpatient visits increased by 200% and 300%, respectively. Patients with pain crises had approximately twice the number of inpatient episodes and outpatient visit per year, and had higher productivity losses compared to patients without crises. Conclusion In an era of emerging treatments for SCD, we have, to the best of our knowledge, for the first time comprehensively described epidemiological and economic aspects of SCD in a country where the disease is still rare and not well recognized by the healthcare system.
镰状细胞病(SCD)是一组遗传性血红蛋白疾病。在全球范围内,每年约有30万至40万新生儿患有SCD,在疟疾流行国家最为普遍。然而,移民已经影响了SCD的流行病学,但这方面的数据很少。本研究的目的是描述瑞典SCD的流行病学、治疗吸收和经济负担,瑞典是一个过去几十年有大量移民的国家。方法本研究选取了2001年至2018年的SCD患者,并对其进行了2006年至2018年的随访。利用高质量的瑞典人口登记数据,我们估计了患病率、治疗接受情况、与scd相关的卫生保健资源使用、病假和残疾养恤金。结果2006年至2018年,SCD患者数量从504例增加到670例;住院和门诊分别增加了200%和300%。有疼痛危机的患者每年住院次数和门诊次数大约是住院次数和门诊次数的两倍,与没有疼痛危机的患者相比,他们的生产力损失更高。在一个新兴的SCD治疗方法的时代,我们已经,据我们所知,第一次全面描述了SCD的流行病学和经济方面,在一个疾病仍然罕见,没有很好地认识到卫生保健系统的国家。
{"title":"Economic burden of sickle cell disease in Sweden: a population-based national register study with 13 years follow up","authors":"Christian Kjellander, E. Hernlund, M. Ivergård, A. Svedbom, T. Dibbern, A. Stenling, F. Sjöö, S. Vertuani, A. Glenthøj, H. Cherif","doi":"10.3389/frhem.2023.1205941","DOIUrl":"https://doi.org/10.3389/frhem.2023.1205941","url":null,"abstract":"Introduction Sickle cell disease (SCD) describes a group of inherited disorders of hemoglobin. Globally, SCD occurs in approximately 300,000-400,000 births annually and is most prevalent in malaria-endemic countries. However, migration has impacted the epidemiology of SCD but data on the matter are scarce. The objective of this study was to describe the epidemiology, treatment uptake, and economic burden of SCD in Sweden, a country with substantial immigration over the last decades. Methods This nationwide retrospective observational registry cohort study identified patients with SCD from 2001 to 2018 and followed them from 2006 to 2018. Using data from high-quality population-based Swedish registers, we estimated prevalence, treatment uptake, and SCD-related health care resource use, sick leave and disability pension. Results Between 2006 and 2018 the number of patients with SCD increased from 504 to 670; inpatient hospital stays and outpatient visits increased by 200% and 300%, respectively. Patients with pain crises had approximately twice the number of inpatient episodes and outpatient visit per year, and had higher productivity losses compared to patients without crises. Conclusion In an era of emerging treatments for SCD, we have, to the best of our knowledge, for the first time comprehensively described epidemiological and economic aspects of SCD in a country where the disease is still rare and not well recognized by the healthcare system.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129575751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Waldenström Macroglobulinemia diagnosis, risk assessment and treatment in Portugal – results from a Delphi-like Panel Waldenström葡萄牙巨球蛋白血症的诊断、风险评估和治疗——来自德尔菲样小组的结果
Pub Date : 2023-06-26 DOI: 10.3389/frhem.2023.1203369
R. Bergantim, S. Chacim, A. Monteiro, A. M. Macedo, G. Rodrigues, M. G. da Silva
Clinical features of Waldenström Macroglobulinemia (WM) are variable, often leading to heterogeneous decisions regarding patients’ diagnosis, risk stratification, and treatment. This study assessed the agreement rates on WM diagnosis, risk stratification, and active treatment strategies to capture how this heterogeneity may influence national practices among hematologists. A two-round Delphi-like Panel with 22 national hematologists experienced in WM was conducted online, where 33 statements were classified using a 4-point Likert scale. For each statement, the consensus level was set at 70% for “fully agree/disagree”; the majority level was defined as >70% in agreement or disagreement. After two rounds, no statements were categorized as consensus, and 15 out of 33 failed to obtain a qualified majority. Globally, the experts could not reach a qualified majority in approximately half of the sentences from each category (diagnosis, risk assessment, and therapeutic decision), indicating that contradictory opinions are transversal to all the topics involving WM. A lack of consensus in diagnosing and managing WM among Portuguese hematologists became evident. These results illustrate heterogeneity in clinical practices, and future research initiatives should be considered to improve and reinforce accepted guidelines for diagnosing, assessing, and treating WM patients.
Waldenström巨球蛋白血症(WM)的临床特征是多变的,常常导致对患者的诊断、风险分层和治疗的不同决定。本研究评估了WM诊断、风险分层和积极治疗策略的一致性,以捕获这种异质性如何影响血液学家的国家实践。由22名在WM方面有经验的国家血液学家组成的两轮德尔菲式小组在线进行,其中33项陈述使用4点李克特量表进行分类。对于每个陈述,“完全同意/不同意”的共识水平设置为70%;多数水平定义为同意或不同意的比例大于70%。两轮之后,没有一项发言被归类为共识,33人中有15人未能获得特定多数。在全球范围内,专家们无法在每个类别(诊断、风险评估和治疗决策)的大约一半的句子中达到合格多数,这表明矛盾的观点是横向的,涉及WM的所有主题。葡萄牙血液学家在诊断和管理WM方面缺乏共识,这一点很明显。这些结果说明了临床实践的异质性,未来的研究应该考虑改进和加强诊断、评估和治疗WM患者的公认指南。
{"title":"Waldenström Macroglobulinemia diagnosis, risk assessment and treatment in Portugal – results from a Delphi-like Panel","authors":"R. Bergantim, S. Chacim, A. Monteiro, A. M. Macedo, G. Rodrigues, M. G. da Silva","doi":"10.3389/frhem.2023.1203369","DOIUrl":"https://doi.org/10.3389/frhem.2023.1203369","url":null,"abstract":"Clinical features of Waldenström Macroglobulinemia (WM) are variable, often leading to heterogeneous decisions regarding patients’ diagnosis, risk stratification, and treatment. This study assessed the agreement rates on WM diagnosis, risk stratification, and active treatment strategies to capture how this heterogeneity may influence national practices among hematologists. A two-round Delphi-like Panel with 22 national hematologists experienced in WM was conducted online, where 33 statements were classified using a 4-point Likert scale. For each statement, the consensus level was set at 70% for “fully agree/disagree”; the majority level was defined as >70% in agreement or disagreement. After two rounds, no statements were categorized as consensus, and 15 out of 33 failed to obtain a qualified majority. Globally, the experts could not reach a qualified majority in approximately half of the sentences from each category (diagnosis, risk assessment, and therapeutic decision), indicating that contradictory opinions are transversal to all the topics involving WM. A lack of consensus in diagnosing and managing WM among Portuguese hematologists became evident. These results illustrate heterogeneity in clinical practices, and future research initiatives should be considered to improve and reinforce accepted guidelines for diagnosing, assessing, and treating WM patients.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"187 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133670427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global burden and unmet needs in the treatment of transfusion-dependent β-thalassemia 输血依赖性β-地中海贫血治疗的全球负担和未满足需求
Pub Date : 2023-06-20 DOI: 10.3389/frhem.2023.1187681
G. Forni, G. Grazzini, J. Boudreaux, V. Agostini, L. Omert
Beta thalassemia (β-thalassemia) is part of a group of inherited hemoglobinopathies caused by a mutation in the beta globin gene, leading to minimal functional hemoglobin and resulting in damaged red blood cells and anemia. β-Thalassemia is most common in the Mediterranean region, South-East Asia, the Indian subcontinent, and the Middle East. Many of these regions include low- and middle-income countries where there are significant unmet needs in the adequate care and management of thalassemia. Patients with transfusion-dependent β-thalassemia, the most severe form of the disease, require regular blood transfusions. Chronic transfusions are often accompanied by iron chelation therapy to manage ferritin levels. Complications caused by transfusions and iron overload are only partially addressed by current treatment strategies, which negatively affect the quality of life of patients with transfusion-dependent β-thalassemia. Until curative modalities become available for all patients worldwide, methods of optimizing supportive treatments are needed to reduce the symptoms of ineffective erythropoiesis; minimize transfusion-related reactions and side effects; reduce rates of alloimmunization and transfusion-transmitted infections; and to reduce the psychosocial burden on both patients and their caregivers. This review aims to provide an overview and comparison of the ways transfusion-dependent β-thalassemia is identified and treated in different geographic regions, to assess unmet needs specific to these regions, and to discuss how therapies currently in development may improve care.
β-地中海贫血(β-地中海贫血)是一组遗传性血红蛋白病的一部分,由β-珠蛋白基因突变引起,导致血红蛋白功能最低,导致红细胞受损和贫血。β-地中海贫血在地中海区域、东南亚、印度次大陆和中东最为常见。其中许多区域包括低收入和中等收入国家,这些国家在地中海贫血的适当护理和管理方面存在大量未得到满足的需求。输血依赖型β-地中海贫血是该疾病最严重的形式,患者需要定期输血。慢性输注常伴有铁螯合治疗以控制铁蛋白水平。目前的治疗策略只能部分解决由输血和铁超载引起的并发症,这些并发症会对输血依赖性β-地中海贫血患者的生活质量产生负面影响。在全世界所有患者都能获得治疗方法之前,需要优化支持性治疗的方法,以减少无效红细胞生成的症状;尽量减少输血相关的反应和副作用;降低同种异体免疫率和输血传播感染率;并减轻患者及其护理人员的心理负担。本综述旨在概述和比较输血依赖性β-地中海贫血在不同地理区域的识别和治疗方法,评估这些区域未满足的特定需求,并讨论目前正在开发的治疗方法如何改善护理。
{"title":"Global burden and unmet needs in the treatment of transfusion-dependent β-thalassemia","authors":"G. Forni, G. Grazzini, J. Boudreaux, V. Agostini, L. Omert","doi":"10.3389/frhem.2023.1187681","DOIUrl":"https://doi.org/10.3389/frhem.2023.1187681","url":null,"abstract":"Beta thalassemia (β-thalassemia) is part of a group of inherited hemoglobinopathies caused by a mutation in the beta globin gene, leading to minimal functional hemoglobin and resulting in damaged red blood cells and anemia. β-Thalassemia is most common in the Mediterranean region, South-East Asia, the Indian subcontinent, and the Middle East. Many of these regions include low- and middle-income countries where there are significant unmet needs in the adequate care and management of thalassemia. Patients with transfusion-dependent β-thalassemia, the most severe form of the disease, require regular blood transfusions. Chronic transfusions are often accompanied by iron chelation therapy to manage ferritin levels. Complications caused by transfusions and iron overload are only partially addressed by current treatment strategies, which negatively affect the quality of life of patients with transfusion-dependent β-thalassemia. Until curative modalities become available for all patients worldwide, methods of optimizing supportive treatments are needed to reduce the symptoms of ineffective erythropoiesis; minimize transfusion-related reactions and side effects; reduce rates of alloimmunization and transfusion-transmitted infections; and to reduce the psychosocial burden on both patients and their caregivers. This review aims to provide an overview and comparison of the ways transfusion-dependent β-thalassemia is identified and treated in different geographic regions, to assess unmet needs specific to these regions, and to discuss how therapies currently in development may improve care.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"94 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129808093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peripherally inserted central catheter insertion and management in Hodgkin and non-Hodgkin lymphomas: a 13-year monocentric experience 霍奇金淋巴瘤和非霍奇金淋巴瘤13年单中心治疗经验
Pub Date : 2023-06-20 DOI: 10.3389/frhem.2023.1171991
D. Derudas, S. Massidda, M. P. Simula, D. Dessì, S. Usai, G. Longhitano, Daniela Ibba, Loredana Aracu, M. Atzori, G. La Nasa
Background Non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL) are two of the most common hematologic diseases that require an infusion of immunochemotherapies in conjunction with radiotherapy, often in an outpatient setting. For relapsed/refractory disease, autologous peripheral hematopoietic stem cell transplantation and sometimes allogeneic transplantation (HSCT) are considered standard treatment options. Recently, chimeric antigen receptor (CAR) T cells and bispecific antibodies have emerged as an important and effective option for the treatment of relapsed/refractory patients. These medical approaches deserve effective, safe, and durable vascular access, especially for the ambulatory population undergoing discontinuous treatment associated with high rates of complications and life-threatening toxicities. Peripherally inserted central catheters (PICCs) are vascular devices with an intermediate-to-long-term lifespan that are inserted ultrasonically into a peripheral brachial vein. Their ease of insertion by trained nurses and low rate of catheter-related infectious and thrombotic complications make them ideal devices for treating oncology and hematology patients. Purpose In this study, we aim to demonstrate that PICCs are an essential tool for the treatment of HL and NHL patients in terms of efficiency and safety Methods and results From March 2007 to June 2020, 316 PICC implantations were performed by our PICC team in 276 HL patients and 363 PICC in 322 NHL patients. The total lifespan of the PICCs was 50,660 days in HL and 43,919 days in NHL patients. Most PICCs were removed at the end of therapy, and the rate of mechanical complications was low. Only one and four episodes of confirmed PICC-related catheter-related bloodstream infections (CRBSIs) (0.3%; 0.02/1,000 days/PICC and 1.2%; 0.07/1,000 days/PICC) were recorded in HL and NHL patients, respectively. There were only 11 (3.6%; 0.25/1,000 days/PICC) and nine (2.6%; 0.17/1,000 days/PICC) episodes of symptomatic PICC-related thrombotic complications in HL and NHL patients, respectively, without removal. Conclusion Our data indicate that the PICC can be considered the device of choice for treating HL and NHL patients because it is easy to insert, safe to use, long-lasting, and has a low complication rate, especially in the outpatient setting.
背景:非霍奇金淋巴瘤(NHL)和霍奇金淋巴瘤(HL)是两种最常见的血液病,需要在放射治疗的同时输注免疫化疗,通常在门诊进行。对于复发/难治性疾病,自体外周造血干细胞移植和有时异体移植(HSCT)被认为是标准的治疗选择。最近,嵌合抗原受体(CAR) T细胞和双特异性抗体已成为治疗复发/难治性患者的重要而有效的选择。这些医疗方法应该得到有效、安全和持久的血管通路,特别是对于正在接受与高并发症和危及生命的毒性相关的不连续治疗的门诊人群。外周插入中心导管(PICCs)是一种具有中长期使用寿命的血管装置,通过超声插入外周肱静脉。它们易于由训练有素的护士插入,并且导管相关的感染和血栓并发症发生率低,使其成为治疗肿瘤和血液学患者的理想设备。在这项研究中,我们的目的是证明PICC在治疗HL和NHL患者的效率和安全性方面是必不可少的工具,方法和结果从2007年3月到2020年6月,我们的PICC团队对276名HL患者进行了316例PICC植入,对322名NHL患者进行了363例PICC植入。在HL患者中picc的总寿命为50660天,在NHL患者中为43919天。大多数picc在治疗结束时被移除,机械并发症的发生率很低。确诊picc相关导管相关性血流感染(crbsi)仅1次和4次(0.3%;0.02/ 1000天/PICC和1.2%;在HL和NHL患者中分别记录了0.07/ 1000天/PICC)。仅有11例(3.6%;0.25/ 1000天/PICC)和9 (2.6%;在不切除的情况下,HL和NHL患者的症状性PICC相关血栓性并发症发生率分别为0.17/ 1000天/PICC)。结论我们的数据表明PICC可以被认为是治疗HL和NHL患者的首选装置,因为它易于插入,使用安全,使用时间长,并发症发生率低,特别是在门诊。
{"title":"Peripherally inserted central catheter insertion and management in Hodgkin and non-Hodgkin lymphomas: a 13-year monocentric experience","authors":"D. Derudas, S. Massidda, M. P. Simula, D. Dessì, S. Usai, G. Longhitano, Daniela Ibba, Loredana Aracu, M. Atzori, G. La Nasa","doi":"10.3389/frhem.2023.1171991","DOIUrl":"https://doi.org/10.3389/frhem.2023.1171991","url":null,"abstract":"Background Non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL) are two of the most common hematologic diseases that require an infusion of immunochemotherapies in conjunction with radiotherapy, often in an outpatient setting. For relapsed/refractory disease, autologous peripheral hematopoietic stem cell transplantation and sometimes allogeneic transplantation (HSCT) are considered standard treatment options. Recently, chimeric antigen receptor (CAR) T cells and bispecific antibodies have emerged as an important and effective option for the treatment of relapsed/refractory patients. These medical approaches deserve effective, safe, and durable vascular access, especially for the ambulatory population undergoing discontinuous treatment associated with high rates of complications and life-threatening toxicities. Peripherally inserted central catheters (PICCs) are vascular devices with an intermediate-to-long-term lifespan that are inserted ultrasonically into a peripheral brachial vein. Their ease of insertion by trained nurses and low rate of catheter-related infectious and thrombotic complications make them ideal devices for treating oncology and hematology patients. Purpose In this study, we aim to demonstrate that PICCs are an essential tool for the treatment of HL and NHL patients in terms of efficiency and safety Methods and results From March 2007 to June 2020, 316 PICC implantations were performed by our PICC team in 276 HL patients and 363 PICC in 322 NHL patients. The total lifespan of the PICCs was 50,660 days in HL and 43,919 days in NHL patients. Most PICCs were removed at the end of therapy, and the rate of mechanical complications was low. Only one and four episodes of confirmed PICC-related catheter-related bloodstream infections (CRBSIs) (0.3%; 0.02/1,000 days/PICC and 1.2%; 0.07/1,000 days/PICC) were recorded in HL and NHL patients, respectively. There were only 11 (3.6%; 0.25/1,000 days/PICC) and nine (2.6%; 0.17/1,000 days/PICC) episodes of symptomatic PICC-related thrombotic complications in HL and NHL patients, respectively, without removal. Conclusion Our data indicate that the PICC can be considered the device of choice for treating HL and NHL patients because it is easy to insert, safe to use, long-lasting, and has a low complication rate, especially in the outpatient setting.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116782310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Report: A rare case of CD20-positive T-cell large granular lymphocyte leukemia with renal cell carcinoma: a challenging diagnosis 病例报告:一例罕见的cd20阳性t细胞大颗粒淋巴细胞白血病合并肾细胞癌:一个具有挑战性的诊断
Pub Date : 2023-05-30 DOI: 10.3389/frhem.2023.1160049
Y. Jin, F. Ren, Shuyan Wang, Jin Xu, Ying-Hua Wu, Jin-fen Tang, Jianfeng Xu
Large granular lymphocytic leukemia (LGLL) is a clonal lymphoproliferative disease with a slow course and considerable difficulties in correct diagnosis and therapy. T-LGLL is the most prevalent subtype of LGLL, accounting for approximately 85%. T-LGLL co-existence with solid malignancies is relatively rare. CD20-positive T-cell neoplasm is a rare disease in clinics. In this study, we report a case of CD20-positive T-LGLL with renal cell carcinoma (RCC) that was eventually diagnosed by splenectomy and nephrectomy. The accumulation of cases will contribute to diagnosing and treating CD20-positive T-LGLL complicated with solid tumors.
大颗粒淋巴细胞白血病(LGLL)是一种克隆性淋巴细胞增生性疾病,病程缓慢,正确诊断和治疗相当困难。T-LGLL是LGLL中最常见的亚型,约占85%。T-LGLL与实体恶性肿瘤共存是相对罕见的。cd20阳性t细胞肿瘤是临床上罕见的疾病。在这项研究中,我们报告了一例cd20阳性T-LGLL合并肾细胞癌(RCC),最终通过脾切除术和肾切除术诊断。病例的积累将有助于cd20阳性T-LGLL合并实体瘤的诊断和治疗。
{"title":"Case Report: A rare case of CD20-positive T-cell large granular lymphocyte leukemia with renal cell carcinoma: a challenging diagnosis","authors":"Y. Jin, F. Ren, Shuyan Wang, Jin Xu, Ying-Hua Wu, Jin-fen Tang, Jianfeng Xu","doi":"10.3389/frhem.2023.1160049","DOIUrl":"https://doi.org/10.3389/frhem.2023.1160049","url":null,"abstract":"Large granular lymphocytic leukemia (LGLL) is a clonal lymphoproliferative disease with a slow course and considerable difficulties in correct diagnosis and therapy. T-LGLL is the most prevalent subtype of LGLL, accounting for approximately 85%. T-LGLL co-existence with solid malignancies is relatively rare. CD20-positive T-cell neoplasm is a rare disease in clinics. In this study, we report a case of CD20-positive T-LGLL with renal cell carcinoma (RCC) that was eventually diagnosed by splenectomy and nephrectomy. The accumulation of cases will contribute to diagnosing and treating CD20-positive T-LGLL complicated with solid tumors.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124030260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Report: Thrombopoietin receptor agonists in resistant thrombocytopenia in pregnancy: a case series and review of literature 病例报告:血小板生成素受体激动剂治疗妊娠期抵抗性血小板减少症:病例系列和文献回顾
Pub Date : 2023-05-15 DOI: 10.3389/frhem.2023.1180156
G. Sayed, S. Elkourashy, M. Alnajjar, Naela Al Mallahi, Shehab Fareed
Immune thrombocytopenia (ITP) affects 0.1 to 1 per 1000 pregnancies and severe ITP, with platelet counts less than 10,000/µL, is difficult to manage. Two pregnant patients with ITP who were successfully treated with thrombopoietin receptor agonists (TPO-RA) at a tertiary institution are discussed. The first patient had chronic ITP, achieved complete remission with eltrombopag, but was resistant to intravenous immunoglobulin (IVIG) and steroids in her second pregnancy. Romiplostim was effective, and she had an uneventful cesarean section. The second patient responded well to eltrombopag at 35 weeks of gestation and had a vaginal delivery. ITP in pregnancy is managed based on clinical expertise, and TPO-RA use during pregnancy is largely from case reports. For severe ITP, eltrombopag or romiplostim from around 34 weeks can be used if other treatments fail, with a goal of achieving a platelet count of over 80,000/µL. The mother’s response to medication may vary in different pregnancies. Induction of labor may be appropriate in some cases.
免疫性血小板减少症(ITP)影响每1000例妊娠中0.1至1例,严重的ITP,血小板计数低于10,000/µL,难以控制。本文讨论了两名妊娠ITP患者,他们成功地接受了血小板生成素受体激动剂(TPO-RA)的治疗。第一位患者患有慢性ITP,使用依曲波帕完全缓解,但在第二次怀孕时静脉注射免疫球蛋白(IVIG)和类固醇耐药。Romiplostim是有效的,她进行了一次顺利的剖宫产手术。第二位患者在妊娠35周时对依曲波巴反应良好,并顺产。妊娠期ITP的管理基于临床专业知识,妊娠期TPO-RA的使用主要来自病例报告。对于严重的ITP,如果其他治疗失败,可以从34周左右开始使用电子曲巴格或罗米普罗stim,目标是实现血小板计数超过80,000/µL。母亲对药物的反应可能在不同的怀孕期间有所不同。在某些情况下,引产可能是合适的。
{"title":"Case Report: Thrombopoietin receptor agonists in resistant thrombocytopenia in pregnancy: a case series and review of literature","authors":"G. Sayed, S. Elkourashy, M. Alnajjar, Naela Al Mallahi, Shehab Fareed","doi":"10.3389/frhem.2023.1180156","DOIUrl":"https://doi.org/10.3389/frhem.2023.1180156","url":null,"abstract":"Immune thrombocytopenia (ITP) affects 0.1 to 1 per 1000 pregnancies and severe ITP, with platelet counts less than 10,000/µL, is difficult to manage. Two pregnant patients with ITP who were successfully treated with thrombopoietin receptor agonists (TPO-RA) at a tertiary institution are discussed. The first patient had chronic ITP, achieved complete remission with eltrombopag, but was resistant to intravenous immunoglobulin (IVIG) and steroids in her second pregnancy. Romiplostim was effective, and she had an uneventful cesarean section. The second patient responded well to eltrombopag at 35 weeks of gestation and had a vaginal delivery. ITP in pregnancy is managed based on clinical expertise, and TPO-RA use during pregnancy is largely from case reports. For severe ITP, eltrombopag or romiplostim from around 34 weeks can be used if other treatments fail, with a goal of achieving a platelet count of over 80,000/µL. The mother’s response to medication may vary in different pregnancies. Induction of labor may be appropriate in some cases.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"6 11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122108620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience CAR - t细胞治疗后hsct患者的预后和管理:单中心经验
Pub Date : 2023-05-10 DOI: 10.3389/frhem.2023.1151744
C. Phillips, Christa Krupski, Ruby Khoury, C. Dandoy, A. Nelson, Thomas J. Galletta, Angela Faulhaber, S. Davies, Jeremy D. Rubinstein
Background Tisagenlecleucel (tisa-cel) is increasingly being used in hematopoietic stem cell transplantation (HSCT)-naive patients. Outcomes for HSCT patients following chimeric antigen receptor (CAR) T-cell therapy demonstrate low relapse rates; however, a significant number of patients who receive tisa-cel can maintain remission without an HSCT. Multiple factors are considered when choosing whether or not to proceed with HSCT. Methods We retrospectively reviewed 31 patients who had received tisa-cel at our institution and who were transplant naive at the time of infusion. The aim was to determine the rate and timing of consolidative HSCT, factors that led to HSCT, and overall survival. Results Three of the 31 patients were non-responders to tisa-cel and ultimately died of disease. Twelve of the 28 responders remain alive with no evidence of disease (NED) without subsequent therapy. Of these patients, 5 of the 12 had isolated extramedullary acute lymphoblastic leukemia (ALL) (CNS, n = 4; testes, n = 1) and 2 of the 12 had Down syndrome, so no transplantation was planned. In the remaining 5 of 12 patients, close monitoring for signs of relapsed ALL, using serial next-generation sequencing (NGS) minimal residual disease (MRD) and lymphocyte subpopulation measurements, was performed. Owing to continued negative findings, no HSCT was chosen. Ultimately, 43% (12 of 28) of responders proceeded to HSCT, with three receiving tisa-cel as a planned bridge to HSCT as a result of CD22 negativity and/or provider preference (two patients survived with NED); three proceeded to HSCT as a result of early loss of B-cell aplasia (BCA) (all survived with NED); and six had salvage HSCT following relapse (three patients survived with NED and one patient was alive in relapse). Three of the 28 patients died following relapse post CAR T-cell therapy without HSCT. The final patient had an isolated extramedullary soft tissue CD19+ relapse 1 year post tisa-cel treatment, and is now NED without HSCT and persistent BCA. Conclusion Close monitoring of NGS results and BCA, as well as consideration of the site of the disease, can spare a subset of patients HSCT with the maintenance of leukemia-free remission, while still allowing for later HSCT in others. In our cohort, only a small subset of patients was unable to proceed to HSCT following relapse post-CAR T-cell therapy.
Tisagenlecleucel(组织细胞)越来越多地用于造血干细胞移植(HSCT)初治患者。嵌合抗原受体(CAR) t细胞治疗后的HSCT患者复发率低;然而,相当一部分接受组织细胞移植的患者在不接受造血干细胞移植的情况下也能维持缓解。在选择是否进行HSCT时,要考虑多种因素。方法回顾性分析31例在本院接受组织细胞移植并在输注时进行移植的患者。目的是确定巩固性HSCT的发生率和时间,导致HSCT的因素和总生存率。结果31例患者中有3例对组织细胞治疗无反应,最终死于疾病。在没有后续治疗的情况下,28例应答者中有12例存活且无疾病迹象(NED)。在这些患者中,12例中有5例患有分离性髓外急性淋巴细胞白血病(ALL) (CNS, n = 4;12例患者中有2例患有唐氏综合症,因此没有移植计划。在12例患者中的其余5例中,使用串行下一代测序(NGS)最小残留病(MRD)和淋巴细胞亚群测量密切监测复发性ALL的迹象。由于持续的阴性结果,没有选择HSCT。最终,43%(28人中有12人)的应答者进行了HSCT治疗,其中3人接受了组织细胞治疗,因为CD22阴性和/或提供者偏好(2例患者存活于NED);3例由于早期b细胞发育不全(BCA)的丧失而进行了HSCT(所有患者都存活于NED);6例患者复发后进行了补救性HSCT(3例患者因NED存活,1例患者复发后存活)。28例患者中有3例在CAR - t细胞治疗后复发死亡。最后一位患者在组织细胞治疗1年后出现了孤立的髓外软组织CD19+复发,现在是NED,没有HSCT和持续性BCA。结论:密切监测NGS结果和BCA,并考虑疾病的部位,可以避免一部分患者进行HSCT,维持无白血病缓解,同时仍然允许其他患者进行后续HSCT。在我们的队列中,只有一小部分患者在car - t细胞治疗后复发后无法进行HSCT。
{"title":"Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience","authors":"C. Phillips, Christa Krupski, Ruby Khoury, C. Dandoy, A. Nelson, Thomas J. Galletta, Angela Faulhaber, S. Davies, Jeremy D. Rubinstein","doi":"10.3389/frhem.2023.1151744","DOIUrl":"https://doi.org/10.3389/frhem.2023.1151744","url":null,"abstract":"Background Tisagenlecleucel (tisa-cel) is increasingly being used in hematopoietic stem cell transplantation (HSCT)-naive patients. Outcomes for HSCT patients following chimeric antigen receptor (CAR) T-cell therapy demonstrate low relapse rates; however, a significant number of patients who receive tisa-cel can maintain remission without an HSCT. Multiple factors are considered when choosing whether or not to proceed with HSCT. Methods We retrospectively reviewed 31 patients who had received tisa-cel at our institution and who were transplant naive at the time of infusion. The aim was to determine the rate and timing of consolidative HSCT, factors that led to HSCT, and overall survival. Results Three of the 31 patients were non-responders to tisa-cel and ultimately died of disease. Twelve of the 28 responders remain alive with no evidence of disease (NED) without subsequent therapy. Of these patients, 5 of the 12 had isolated extramedullary acute lymphoblastic leukemia (ALL) (CNS, n = 4; testes, n = 1) and 2 of the 12 had Down syndrome, so no transplantation was planned. In the remaining 5 of 12 patients, close monitoring for signs of relapsed ALL, using serial next-generation sequencing (NGS) minimal residual disease (MRD) and lymphocyte subpopulation measurements, was performed. Owing to continued negative findings, no HSCT was chosen. Ultimately, 43% (12 of 28) of responders proceeded to HSCT, with three receiving tisa-cel as a planned bridge to HSCT as a result of CD22 negativity and/or provider preference (two patients survived with NED); three proceeded to HSCT as a result of early loss of B-cell aplasia (BCA) (all survived with NED); and six had salvage HSCT following relapse (three patients survived with NED and one patient was alive in relapse). Three of the 28 patients died following relapse post CAR T-cell therapy without HSCT. The final patient had an isolated extramedullary soft tissue CD19+ relapse 1 year post tisa-cel treatment, and is now NED without HSCT and persistent BCA. Conclusion Close monitoring of NGS results and BCA, as well as consideration of the site of the disease, can spare a subset of patients HSCT with the maintenance of leukemia-free remission, while still allowing for later HSCT in others. In our cohort, only a small subset of patients was unable to proceed to HSCT following relapse post-CAR T-cell therapy.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125107446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent progress in analyses of GATA1 in hematopoietic disorders: a mini-review GATA1在造血疾病分析中的最新进展:综述
Pub Date : 2023-05-03 DOI: 10.3389/frhem.2023.1181216
R. Shimizu, Masayuki Yamamoto
GATA1 is an essential master regulator of erythropoiesis and megakaryopoiesis. Accumulating lines of evidence have shown that dynamic changes in GATA1 gene expression levels during erythropoiesis are crucial for proper erythroid differentiation. Since GATA1 is an X-chromosome gene, GATA1 knockout leads to embryonic lethal dyserythropoiesis in male mice, while heterozygous female mice can survive. In the past decade, it has become clear that germline GATA1 gene mutations leading to structural changes in the GATA1 protein are involved in congenital dyserythropoiesis in males. In contrast, decreased GATA1 expression levels, which cause embryonic lethal dyserythropoiesis in male mice, increase the risk of erythroleukemia development in female mice, while female GATA1-knockout mice do not show substantial phenotypic alterations in erythroid or megakaryocyte lineages. In this review, we summarize the recent progress in elucidating the roles of GATA1 in normal and pathogenetic erythropoiesis and discuss the possible mechanisms of pathogenesis of dyserythropoiesis and erythroleukemia.
GATA1是红细胞生成和巨核生成的重要主调控因子。越来越多的证据表明,在红细胞生成过程中,GATA1基因表达水平的动态变化对红细胞的正常分化至关重要。由于GATA1是一个x染色体基因,敲除GATA1会导致雄性小鼠胚胎致死性红细胞增生,而杂合的雌性小鼠可以存活。在过去的十年中,人们已经清楚地发现,生殖系GATA1基因突变导致GATA1蛋白的结构变化与男性先天性红细胞生成有关。相反,导致雄性小鼠胚胎致死性红细胞生成的GATA1表达水平降低,增加了雌性小鼠红细胞白血病发生的风险,而雌性GATA1敲除小鼠在红细胞或巨核细胞谱系中没有显示出实质性的表型改变。本文就GATA1在正常红细胞生成和病理性红细胞生成中的作用的最新研究进展进行综述,并对其在红细胞生成和红细胞白血病中的可能机制进行探讨。
{"title":"Recent progress in analyses of GATA1 in hematopoietic disorders: a mini-review","authors":"R. Shimizu, Masayuki Yamamoto","doi":"10.3389/frhem.2023.1181216","DOIUrl":"https://doi.org/10.3389/frhem.2023.1181216","url":null,"abstract":"GATA1 is an essential master regulator of erythropoiesis and megakaryopoiesis. Accumulating lines of evidence have shown that dynamic changes in GATA1 gene expression levels during erythropoiesis are crucial for proper erythroid differentiation. Since GATA1 is an X-chromosome gene, GATA1 knockout leads to embryonic lethal dyserythropoiesis in male mice, while heterozygous female mice can survive. In the past decade, it has become clear that germline GATA1 gene mutations leading to structural changes in the GATA1 protein are involved in congenital dyserythropoiesis in males. In contrast, decreased GATA1 expression levels, which cause embryonic lethal dyserythropoiesis in male mice, increase the risk of erythroleukemia development in female mice, while female GATA1-knockout mice do not show substantial phenotypic alterations in erythroid or megakaryocyte lineages. In this review, we summarize the recent progress in elucidating the roles of GATA1 in normal and pathogenetic erythropoiesis and discuss the possible mechanisms of pathogenesis of dyserythropoiesis and erythroleukemia.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114839520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of haemoglobinopathies on asymptomatic Plasmodium falciparum infection and naturally acquired immunity among children in Northern Ghana 血红蛋白病对加纳北部儿童无症状恶性疟原虫感染和自然获得免疫的影响
Pub Date : 2023-04-25 DOI: 10.3389/frhem.2023.1150134
Helena Lamptey, Zakaria Seidu, Mary Lopez-Perez, Eric Kyei-Baafour, L. Hviid, G. Adjei, M. Ofori
Background The protective effect of certain haemoglobinopathies, such as HbS, HbC, and α-thalassaemia, against severe malaria has long been established; however, there is only limited and equivocal evidence regarding their impact on asymptomatic parasitaemia. Here, we investigated the effect of HbS, HbC, and α-thalassaemia on asymptomatic P. falciparum parasitaemia and acquired immunity among children in Northern Ghana. Materials and methods A cross-sectional study was conducted among 1,017 healthy children (1-17 years) in 13 malaria-endemic communities in Northern Ghana. The children were screened for structural Hb phenotypes using SickleSCAN, for P. falciparum infection using anti-HRP2 malaria RDT and subsequently confirmed by capillary electrophoresis and PCR, respectively. α-thalassaemia genotyping was done using PCR. Levels of IgG specific for six recombinant malaria antigens (PfCSP, GLURP, MSP3, Pfs230, HB3VAR06, and IT4VAR60) and crude asexual blood-stage antigens were evaluated by ELISA. Results 266 out of the 1,017 participants had either HbAC (18%) or HbAS (8.4%), whereas 35% had α‐thalassaemia. Twenty-five percent and 6% HbAC individuals co-inherited heterozygous and homozygous α-thalassaemia respectively. Similarly, 25% and 10.5% of HbAS co-inherited heterozygous and homozygous α-thalassaemia. Asymptomatic parasitaemia rates were 23%, 24%, and 19% in those with HbAA, HbAC and HbAS, respectively. The overall parasite carriage rates in heterozygous (21%) and homozygous α-thalassaemia (25%) individuals were similar to that of individuals without α-thalassaemia (23%). P. falciparum parasite carriage risk was about three times higher among homozygous α-thalassaemia individuals with HbAC (OR = 2.97; 95% CI 0.83-10.62) and heterozygous carriers with HbAS variants (OR = 2.86; 95% CI 0.85-9.60) compared to the wildtype. In HbAS individuals, IgG levels to IT4VAR60 and HB3VAR06 were significantly lower, whereas anti-CSP levels were higher than in HbAA and HbAC. Conclusions Co-inheritance of HbAS and HbAC with α-thalassaemia increased the risk of asymptomatic parasitaemia, an indication of a negative epistatic effect between these Hb variants. Antibody levels against non-PfEMP1 antigens were slightly higher among HbAS children, but quite similar in all study groups, indicating differences in parasite exposure.
某些血红蛋白疾病,如HbS、HbC和α-地中海贫血,对严重疟疾的保护作用早已确立;然而,关于它们对无症状寄生虫病的影响,只有有限和模棱两可的证据。在这里,我们研究了HbS、HbC和α-地中海贫血对加纳北部儿童无症状恶性疟原虫寄生虫病和获得性免疫的影响。材料和方法在加纳北部13个疟疾流行社区的1,017名健康儿童(1-17岁)中进行了一项横断面研究。使用SickleSCAN筛查儿童Hb结构表型,使用抗hrp2疟疾RDT筛查恶性疟原虫感染,随后分别通过毛细管电泳和PCR确认。采用PCR方法进行α-地中海贫血基因分型。ELISA法检测6种重组疟疾抗原(PfCSP、GLURP、MSP3、Pfs230、HB3VAR06、IT4VAR60)和原始无性血期抗原的IgG特异性水平。结果1017名参与者中有266人患有HbAC(18%)或HbAS(8.4%),而35%患有α -地中海贫血。25%和6%的HbAC个体分别共遗传杂合型和纯合型α-地中海贫血。同样,25%和10.5%的HbAS共同遗传杂合型和纯合型α-地中海贫血。无症状寄生虫血症发生率在HbAA、HbAC和HbAS患者中分别为23%、24%和19%。杂合子α-地中海贫血个体(21%)和纯合子α-地中海贫血个体(25%)的总体寄生虫携带率与非α-地中海贫血个体(23%)相似。纯合子α-地中海贫血患者携带恶性疟原虫的风险约为HbAC患者的3倍(OR = 2.97;95% CI 0.83-10.62)和HbAS变异的杂合携带者(OR = 2.86;95% CI 0.85-9.60)。HbAS个体IT4VAR60和HB3VAR06的IgG水平明显低于HbAA和HbAC,而抗csp水平高于HbAA和HbAC。结论HbAS和HbAC与α-地中海贫血的共同遗传增加了无症状寄生虫血症的风险,表明这些Hb变体之间存在负的遗传效应。针对非pfemp1抗原的抗体水平在HbAS儿童中略高,但在所有研究组中非常相似,表明寄生虫暴露的差异。
{"title":"Impact of haemoglobinopathies on asymptomatic Plasmodium falciparum infection and naturally acquired immunity among children in Northern Ghana","authors":"Helena Lamptey, Zakaria Seidu, Mary Lopez-Perez, Eric Kyei-Baafour, L. Hviid, G. Adjei, M. Ofori","doi":"10.3389/frhem.2023.1150134","DOIUrl":"https://doi.org/10.3389/frhem.2023.1150134","url":null,"abstract":"Background The protective effect of certain haemoglobinopathies, such as HbS, HbC, and α-thalassaemia, against severe malaria has long been established; however, there is only limited and equivocal evidence regarding their impact on asymptomatic parasitaemia. Here, we investigated the effect of HbS, HbC, and α-thalassaemia on asymptomatic P. falciparum parasitaemia and acquired immunity among children in Northern Ghana. Materials and methods A cross-sectional study was conducted among 1,017 healthy children (1-17 years) in 13 malaria-endemic communities in Northern Ghana. The children were screened for structural Hb phenotypes using SickleSCAN, for P. falciparum infection using anti-HRP2 malaria RDT and subsequently confirmed by capillary electrophoresis and PCR, respectively. α-thalassaemia genotyping was done using PCR. Levels of IgG specific for six recombinant malaria antigens (PfCSP, GLURP, MSP3, Pfs230, HB3VAR06, and IT4VAR60) and crude asexual blood-stage antigens were evaluated by ELISA. Results 266 out of the 1,017 participants had either HbAC (18%) or HbAS (8.4%), whereas 35% had α‐thalassaemia. Twenty-five percent and 6% HbAC individuals co-inherited heterozygous and homozygous α-thalassaemia respectively. Similarly, 25% and 10.5% of HbAS co-inherited heterozygous and homozygous α-thalassaemia. Asymptomatic parasitaemia rates were 23%, 24%, and 19% in those with HbAA, HbAC and HbAS, respectively. The overall parasite carriage rates in heterozygous (21%) and homozygous α-thalassaemia (25%) individuals were similar to that of individuals without α-thalassaemia (23%). P. falciparum parasite carriage risk was about three times higher among homozygous α-thalassaemia individuals with HbAC (OR = 2.97; 95% CI 0.83-10.62) and heterozygous carriers with HbAS variants (OR = 2.86; 95% CI 0.85-9.60) compared to the wildtype. In HbAS individuals, IgG levels to IT4VAR60 and HB3VAR06 were significantly lower, whereas anti-CSP levels were higher than in HbAA and HbAC. Conclusions Co-inheritance of HbAS and HbAC with α-thalassaemia increased the risk of asymptomatic parasitaemia, an indication of a negative epistatic effect between these Hb variants. Antibody levels against non-PfEMP1 antigens were slightly higher among HbAS children, but quite similar in all study groups, indicating differences in parasite exposure.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125218338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Development of the sickle Pan-African research consortium registry in Tanzania: opportunity to harness data science for sickle cell disease 在坦桑尼亚发展泛非镰状细胞研究联盟登记:利用数据科学治疗镰状细胞病的机会
Pub Date : 2023-04-11 DOI: 10.3389/frhem.2023.1040720
D. Kandonga, Raphael Zozimus Sangeda, U. Masamu, Eliah Kazumali, A. Jonathan, M. Msangawale, Winfrida T. Kaihula, Julieth Rwegalulila, Jesca Ondego, H. Tutuba, J. Ndunguru, Emmanuela E Ambrose, B. Kidenya, Mbonea Yonazi, I. Kyomugisha, Wilson Mupfururirwa, Mario Jonas, V. Nembaware, G. Mazandu, A. Kengne, A. Wonkam, J. Makani, E. Balandya
Background Sickle cell disease (SCD) is a severe hereditary form of anemia that contributes between 50% and 80% of under-five mortality in Africa. Eleven thousand babies are born with SCD annually in Tanzania, ranking 4th after Nigeria, the Democratic Republic of Congo and India. The absence of well-described SCD cohorts is a major barrier to health research in SCD in Africa. Objective This paper describes the Sickle Pan African Consortium (SPARCO) database in Tanzania, from the development, design of the study instruments, data collection, analysis of data and management of data quality issues. Methods The SPARCO registry used existing Muhimbili Sickle Cell Cohort (MSC) study case report forms (CRF) and later harmonized data elements from the SickleInAfrica consortium to develop Research Electronic Data Capture (REDCap) instruments. Patients were enrolled through various strategies, including mass screening following media sensitization and health education events during World Sickle Cell Day each June and the SCD awareness month in September. Additional patients were identified through active surveillance of previously participating patients in the MSC. Results Three thousand eight hundred patients were enrolled between October 2017 and May 2021. Of these, 1,946 (51.21%) were males and 1,864 (48.79%) were females. The hemoglobin phenotype distribution was 3,762 (99%) HbSS, 3 (0.08%) HbSC and 35 (0.92%) HbSβ +thalassemia. Hemoglobin levels, admission history, blood transfusion and painful events were recorded from December 2017 to May 2021. Conclusion The Tanzania SPARCO registry will improve healthcare for SCD in Africa through the facilitation of collaborative data-driven research for SCD.
镰状细胞病(SCD)是一种严重的遗传性贫血,占非洲五岁以下儿童死亡率的50%至80%。坦桑尼亚每年有1.1万名婴儿出生时患有SCD,仅次于尼日利亚、刚果民主共和国和印度,排名第四。缺乏描述良好的慢性阻塞性肺病队列是非洲慢性阻塞性肺病健康研究的主要障碍。目的介绍坦桑尼亚泛非镰刀联盟(SPARCO)数据库的开发、研究仪器的设计、数据收集、数据分析和数据质量管理等问题。方法SPARCO登记处使用现有的Muhimbili镰状细胞队列(MSC)研究病例报告表格(CRF)和后来来自SickleInAfrica联盟的协调数据元素来开发研究电子数据捕获(REDCap)仪器。通过各种策略招募患者,包括在每年6月的世界镰状细胞日和9月的SCD宣传月期间进行媒体致敏和健康教育活动后进行大规模筛查。通过对先前参与MSC的患者进行积极监测,确定了其他患者。结果在2017年10月至2021年5月期间入组了3800名患者。其中男性1946例(51.21%),女性1864例(48.79%)。血红蛋白表型分布为3762 (99%)HbSS, 3 (0.08%) HbSC和35 (0.92%)HbSβ +地中海贫血。记录2017年12月至2021年5月期间的血红蛋白水平、入院史、输血和疼痛事件。坦桑尼亚SPARCO登记处将通过促进数据驱动的SCD合作研究,改善非洲SCD的医疗保健。
{"title":"Development of the sickle Pan-African research consortium registry in Tanzania: opportunity to harness data science for sickle cell disease","authors":"D. Kandonga, Raphael Zozimus Sangeda, U. Masamu, Eliah Kazumali, A. Jonathan, M. Msangawale, Winfrida T. Kaihula, Julieth Rwegalulila, Jesca Ondego, H. Tutuba, J. Ndunguru, Emmanuela E Ambrose, B. Kidenya, Mbonea Yonazi, I. Kyomugisha, Wilson Mupfururirwa, Mario Jonas, V. Nembaware, G. Mazandu, A. Kengne, A. Wonkam, J. Makani, E. Balandya","doi":"10.3389/frhem.2023.1040720","DOIUrl":"https://doi.org/10.3389/frhem.2023.1040720","url":null,"abstract":"Background Sickle cell disease (SCD) is a severe hereditary form of anemia that contributes between 50% and 80% of under-five mortality in Africa. Eleven thousand babies are born with SCD annually in Tanzania, ranking 4th after Nigeria, the Democratic Republic of Congo and India. The absence of well-described SCD cohorts is a major barrier to health research in SCD in Africa. Objective This paper describes the Sickle Pan African Consortium (SPARCO) database in Tanzania, from the development, design of the study instruments, data collection, analysis of data and management of data quality issues. Methods The SPARCO registry used existing Muhimbili Sickle Cell Cohort (MSC) study case report forms (CRF) and later harmonized data elements from the SickleInAfrica consortium to develop Research Electronic Data Capture (REDCap) instruments. Patients were enrolled through various strategies, including mass screening following media sensitization and health education events during World Sickle Cell Day each June and the SCD awareness month in September. Additional patients were identified through active surveillance of previously participating patients in the MSC. Results Three thousand eight hundred patients were enrolled between October 2017 and May 2021. Of these, 1,946 (51.21%) were males and 1,864 (48.79%) were females. The hemoglobin phenotype distribution was 3,762 (99%) HbSS, 3 (0.08%) HbSC and 35 (0.92%) HbSβ +thalassemia. Hemoglobin levels, admission history, blood transfusion and painful events were recorded from December 2017 to May 2021. Conclusion The Tanzania SPARCO registry will improve healthcare for SCD in Africa through the facilitation of collaborative data-driven research for SCD.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"181 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132702405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Frontiers in hematology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1